Johnson & Johnson (NYSE:JNJ) Stock Holdings Increased by Lincoln National Corp

Posted by Defense World Staff on May 12th, 2023

Lincoln National Corp lifted its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 14.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 107,929 shares of the company’s stock after buying an additional 13,322 shares during the period. Lincoln National Corp’s holdings in Johnson & Johnson were worth $19,066,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock worth $14,975,000 after buying an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its holdings in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after acquiring an additional 82,429 shares during the last quarter. AMI Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock worth $3,244,000 after acquiring an additional 1,475 shares during the last quarter. Equitable Holdings Inc. grew its holdings in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock worth $8,095,000 after acquiring an additional 2,119 shares during the last quarter. Finally, USS Investment Management Ltd grew its holdings in shares of Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock worth $152,488,000 after acquiring an additional 20,528 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on JNJ shares. Raymond James lowered their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Atlantic Securities lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a report on Wednesday, April 19th. Morgan Stanley lifted their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the sale, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.20% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $160.99 on Friday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. The stock has a market capitalization of $418.37 billion, a PE ratio of 33.68, a P/E/G ratio of 2.77 and a beta of 0.53. The stock has a 50-day simple moving average of $158.97 and a 200 day simple moving average of $166.83.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same period in the previous year, the company posted $2.67 earnings per share. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 2.96%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is currently 94.56%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.